Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRK-015 in later-onset Spinal Muscular Atrophy
NCT03921528Phase 2Completed
- Sponsor
- Scholar Rock
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of apitegromab in spinal muscular atrophy (SMA) (3 arms), sponsored by Scholar Rock. Primary endpoints: Revised Hammersmith Scale Total Score at 12 months and Hammersmith Functional Motor Scale Expanded Total Score at 12 months. Started Apr 2019; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03921528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921528.